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a  b  s  t  r  a  c  t
Enterovirus  A71  (EV-A71)  has  emerged  as the  most  important  cause  of  large  outbreaks  of  severe  and
sometimes  fatal  hand,  foot  and  mouth  disease  (HFMD)  across  the  Asia-Paciﬁc  region.  EV-A71  outbreaks
have  been  associated  with  (sub)genogroup  switches,  sometimes  accompanied  by  recombination  events.
Understanding  EV-A71  population  dynamics  is  therefore  essential  for understanding  this  emerging  infec-
tion,  and  may  provide  pivotal  information  for vaccine  development.  Despite  the  public  health  burden  of
EV-A71,  relatively  few EV-A71  complete-genome  sequences  are  available  for analysis  and  from  limited
geographical  localities.  The  availability  of  an  efﬁcient  procedure  for whole-genome  sequencing  would
stimulate  effort  to  generate  more  viral  sequence  data.  Herein,  we report  for  the  ﬁrst time  the  develop-
ment  of  a next-generation  sequencing  based protocol  for  whole-genome  sequencing  of EV-A71  directly
from clinical  specimens.  We  were  able  to  sequence  viruses  of subgenogroup  C4  and  B5, while  RNA  from
culture  materials  of  diverse  EV-A71  subgenogroups  belonging  to  both  genogroup  B  and  C was  success-
fully  ampliﬁed.  The  nature  of  intra-host  genetic  diversity  was  explored  in 22  clinical  samples,  revealing
107  positions  carrying  minor  variants  (ranging  from  0 to 15  variants  per  sample).  Our analysis  of  EV-
A71  strains  sampled  in 2013  showed  that they  all belonged  to  subgenogroup  B5, representing  the  ﬁrst
report  of this  subgenogroup  in  Vietnam.  In  conclusion,  we  have successfully  developed  a high-throughput
next-generation  sequencing-based  assay  for whole-genome  sequencing  of EV-A71  from  clinical  samples.
© 2015  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).. IntroductionEnterovirus A71 (EV-A71) belongs to the Enterovirus A species
f the family Picornaviridae,  and is genetically divided into three
enogroups (A, B, and C). The latter two are further divided into
∗ Corresponding author. Tel.: +84 8 8384009; fax: +84 8 9238904.
E-mail address: tanlv@oucru.org (L.V. Tan).
ttp://dx.doi.org/10.1016/j.jviromet.2015.02.011
166-0934/© 2015 The Authors. Published by Elsevier B.V. This is an open access article usubgenogroups, denoted B0 – 5 and C1 – 5, respectively. Since 1997,
EV-A71 has emerged as the most important cause of large out-
breaks of severe and sometimes fatal hand, foot and mouth disease
(HFMD) across the Asia-Paciﬁc region (Solomon et al., 2010; Xing
et al., 2014). In Vietnam, EV-A71-related HFMD was ﬁrst described
in 2003, and became a notiﬁable illness in 2008. Between 2011
and 2012, more than 200,000 hospitalized cases due to HFMD were
reported in Vietnam, of which 207 died as a consequence of clini-
cal complications (including cardio-pulmonary compromise with
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ulmonary edema or hemorrhage) (Khanh et al., 2012; Nguyen
t al., 2014). There was a strong association between the detection
f EV-A71 and severity and death in this outbreak (Khanh et al.,
012; Nguyen et al., 2014). Although phase III trials of three dif-
erent inactivated EV-A71 vaccines from China were recently com-
leted with 95% protection rates against EV-A71 associated HFMD
Zhu et al., 2014; Zhu et al., 2013; Li et al., 2014), there are currently
o vaccines or speciﬁc antiviral drugs available for EV-A71.
Large EV-A71 outbreaks have been associated with
sub)genogroup switches, sometimes accompanied by recom-
ination events (Solomon et al., 2010; McWilliam Leitch et al.,
012; Tee et al., 2010). Similarly, sequence data from Vietnam
btained between 2005 and 2011 show a subgenogroup switch
rom C5 to C4 in 2011 (Khanh et al., 2012; Tu et al., 2007). Of
ote, this C4 subgenogroup was also associated with the epidemic
n China in 2008 and with a recent outbreak in Cambodia (Xing
t al., 2014; Tan et al., 2011; Seiff, 2012). Interestingly, phylo-
enetic analyses and molecular clock dating suggest that strain
eplacement commonly occurs in EV-A71 (Tan et al., 2011), and
hat emerging subgenogroups may  circulate cryptically in the
ommunity at low prevalence for years and cause mild infection
rior to outbreak emergence (Tee et al., 2010). Critically, it is
nclear whether viral evolution is the driver of emergence and
arge outbreaks of HFMD in Southeast Asia, or a consequence of the
reater number of infected hosts. The former would have profound
mplications for vaccine development, necessitating active surveil-
ance and periodic vaccine updates. Taken together the available
ata highlight the importance of understanding EV-A71 evolution
nd population dynamics within and between endemic countries,
hich may  be essential for understanding and controlling this
merging infection, including vaccine development.
Despite the public health burden of EV-A71, relatively few
∼500) EV-A71 complete genome sequences are available for
nalysis and from limited geographical localities, compared to
4500 sequences of A/H3N2 human inﬂuenza virus alone (Viboud
t al., 2013). Hence, the availability of an efﬁcient procedure for
hole-genome sequencing would be an important step toward
timulating scientiﬁc effort to generate more viral sequence data.
erein, we report the development of a complete genome sequenc-
ng protocol for EV-A71 directly from clinical specimens using
T-PCR ampliﬁcation of three overlapping amplicons and next-
eneration sequencing technology.
. Materials and methods
.1. Patients and Clinical specimens
Samples used in this study were derived from patients enrolled
n an ongoing three-year prospective observational study of HFMD
atients of all severities (including out- and in patients) admitted to
he outpatient clinics, infectious diseases wards, and the paediatric
ntensive care units in three major referral hospitals in Ho Chi Minh
ity, Vietnam. This study utilized 65/82 consecutive EV-A71 RT-
CR positive throat swabs collected in viral transport medium from
atients enrolled between July 2013 and December 2013 at the
ospital for Tropical Diseases (HTD) and Children’s Hospital 2. For
he purpose of assay evaluation, the swabs with a wide range of
iral loads were selected based on real time RT-PCR crossing point
Cp) values of between 24 and 36 (i.e. from high to low viral load).
.2. Virus isolatesAn EV-A71 subgenogroup C4 isolate from a child with HFMD
dmitted to HTD during the 2011 outbreak, and eight different iso-
ates each belonging to a different subgenogroup (Table 2) obtainedethods 215–216 (2015) 30–36 31
from the Department of Biomedical Science, University of Malaya,
Malaysia were used for the initial assessment of assay performance.
2.3. Primer design
Overlapping primer pairs were designed for the ampliﬁcation of
three amplicons spanning the entire EV-A71 genome. The primers
were derived either from previous publications (Khanh et al.,
2012) or newly designed based on the alignment of 279 com-
plete genome sequences of all EV-A71 subgenogroups available
in GenBank (Genogroup A, n = 1; B0, 2; B1, 14; B2, 4; B3, 8; B4,
11; B5, 18; C1, 17; C2, 33; C3, 3; C4, 165; C5, 2, and undeﬁned, 1;
accessed in April 2013). Sequence alignment was performed using
MUSCLE available within the Genieous 7.1.3 software package
(http://www.geneious.com). The resulting alignment was used to
identify conserved regions for selection of PCR primers. The location
of primers was  chosen to generate PCR fragments with an over-
lap of 400 nucleotides (nt) or more, allowing for proper sequence
assembly. To avoid compromise of PCR sensitivity, a maximum of
two degenerate nucleotides were introduced per primer. As a con-
sequence, in some occasions, two or more primers targeting one
genomic region were selected for ampliﬁcation of diverse EV-A71
subgenogroups. Primer sequences, genomic locations, ampliﬁed
fragment lengths, and alignment proﬁles of primer binding sites
are shown in Table 1 and Supplementary Appendix Fig. 1.
2.4. Nucleic acid isolation
Viral RNA was  extracted from 140 l of culture supernatant or
clinical material using the QIAamp viral RNA kit (QIAgen GmbH,
Hilden, Germany), recovered in 50 l of elution buffer (provided
with the kit) and was either immediately subjected to RT-PCR
ampliﬁcation or stored at −80 ◦C for subsequent use.
2.5. RT-PCR
RT-PCR was  performed using SuperScript III One-Step RT-PCR
system with Platinum Taq DNA High Fidelity (Invitrogen, Carlsbad,
CA, USA) in a 25 l reaction consisting of 800 nM of each primer
(Table 1), 12.5 l of 2× reaction buffer (provided with the kit),
0.5 l of SuperScriptIII RT/Platinum Taq High Fidelity mix and 4 l
of template RNA. RT-PCR reaction was performed in a Mastercycler
(Eppendorf, Hamburg, Germany). Cycling conditions are speciﬁed
in Table 1.
2.6. Genome sequencing, sequence assembly and minor variation
detection
For each sample, PCR products were quantiﬁed by a
ﬂuorescence-based dsDNA quantiﬁcation method using the Quant-
iT dsDNA Assay Kit in a Qubit ﬂuorometer (Invitrogen) and then
pooled with an equal quantity of each individual PCR amplicon.
One nanogram of pooled DNA from individual samples was then
subjected to library preparation using the Nextera XT DNA sam-
ple preparation kit (Illumina, San Diego, CA, USA), in which each
sample was assigned to a unique barcode sequence using the Nex-
tera XT Index Kit (Illumina). Sequencing of the prepared library was
carried out using the Miseq reagent kit v2 (300 cycles, Illumina) in
an Illumina Miseq platform. A total of 24 samples were sequenced
in a single run. The reads obtained were processed to remove PCR
primers using CLC Genomics Workbench (QIAgen).
Sequence assembly was  performed using the Genieous 7.1.3
software package utilizing a reference-based mapping tool (i.e. the
consensus sequence was obtained by mapping individual reads of
each sample to a reference sequence). Finally, screening of minor
(sub-consensus) variants was performed using the SNP detection
32 L.V. Tan et al. / Journal of Virological Methods 215–216 (2015) 30–36
Table 1
Primer sequences, location and size of ampliﬁed products.
RT-PCRa Primer Oligo sequence (5′–3′) Orientation Start–endb Genomic locations Product size (Kb)
1 FL5F TTAAAACAGCCTGTGGGTTGYACC Forward 1–24 5′UTR
3.2FL9R ACTAAAGGGTACTTGGACTTVGA Reverse 3180–3158 VP1
2  FL15F GGATTRGTWGGGGAGATAGACCT Forward 2699–2721 VP1
2.1
FL16F GGATTRGTWGGAGAGATAGACCT Forward 2699–2721 VP1
FL17F  GGATTRGTWGGGGAGATAGATCT Forward 2699–2721 VP1
FL18F  GGATTRGTWGGAGAGATAGATCT Forward 2699–2721 VP1
FL19R GTCACTTCAATRTCRCAGTCCAT Reverse 4827–4805 2C
FL20R  GTCACTTCAATRTCRCAATCCAT Reverse 4827–4805 2C
3  FL10F CAAACACCGWATTGAACCTGT Forward 4423–4443 2C
2.9FL3R2 GCTATTCTGGTTATAACAAATTTACC Reverse 7405–7380 3′UTR
Note:
a Thermal cycling conditions of RT-PCR 1: 1 cycle of 60 ◦C, 3 min, 53 ◦C, 30 min, 94 ◦C, 2 min, 45 cycles of 94 ◦C, 15 s, 53 ◦C, 30 s, 68 ◦C, 4 min and 1 cycle of 68 ◦C, 5 min; and
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(including 22 from clinical samples and one from virus culture
material) and one near-complete genome sequence of EV-A71 were
successfully assembled. A coverage of ≥500-fold was  achieved in
22 samples (including 21 clinical samples and the virus isolate) andT-PCR  2 and 3: 1 cycle of 60 ◦C, 3 min, 50 ◦C, 30 min, 94 ◦C, 2 min, 45 cycles of 94 ◦C
b Positions of primers are given based on the genomic sequence of an EV-A71 str
 = A/C/G, R = A/G, W = A/T;
ool available in Geneious. A minimum variant frequency of 5% and
00-fold coverage were chosen as cut-off values.
.7. Sequence analysis of the obtained consensuses
Sequence alignment of the consensus genomes obtained in
his study was performed using MUSCLE (Edgar, 2004), and the
hylogenetic relationships among these data and 25 represen-
ative sequences taken from GenBank were estimated using the
aximum likelihood (ML) PhyML method available within the
eneious package. The ML  phylogenetic analysis utilized the gen-
ral time reversible (GTR) nucleotide substitution model (Guindon
nd Gascuel, 2003), and support for individual nodes was  assessed
sing a bootstrap procedure (1000 replicates).
.8. Sequence accession numbers
The sequences of EV-A71 obtained in this study were sub-
itted to NCBI (GenBank) and assigned accession numbers
P691643–KP691666.
.9. Ethical statement
The studies from which clinical specimens were selected for
se in this study were reviewed and approved by the Institutional
eview Boards of the sites of enrolment in Ho Chi Minh City, Viet-
am and the Oxford Tropical Research Ethics Committee (OxTREC),
niversity of Oxford, Oxford, United Kingdom.
. Results
.1. Whole-genome RT-PCRs
After examining the complete genome sequence alignment of
V-A71, primer pairs for three overlapping RT-PCRs spanning the
hole genome were designed. To assess their performance, we ﬁrst
ested the assays on RNA derived from culture supernatants of dif-
erent EV-A71 subgenogroups. Notably, all three RT-PCRs were able
o amplify viral RNA from each sample (Table 2).
The overlapping PCRs were further tested on 65 EV-A71 RT-PCR-
ositive throat swab samples collected from children with HFMD.
ll three fragments were successfully ampliﬁed in 50/65 (77%) sam-
les (Fig. 1). Eleven out of 15 samples that were not ampliﬁed by
he three overlapping PCRs were due to failure of the 3.2Kb PCRs
details in Supplementary Appendix Table 1). A signiﬁcantly higher
iral load (as suggested by Cp values generated by an EV-A71 real-
ime RT-PCR (Khanh et al., 2012)) was observed among samples
hat were ampliﬁed by all three RT-PCRs compared to samples that 50 ◦C, 30 s, 68 ◦C, 3.5 min  and 1 cycle of 68 ◦C, 5 min.
om Vietnam, Vietnam/540 V/VNM/05/C4 (GenBank accession JQ965759.1); Y = C/T,
were not (Fig. 2). Accordingly, clinical samples with a Cp value of 30
or less allowed the successful ampliﬁcation of the three genomic
fragments.
3.2. Genome sequencing using the Illumina platform
Ampliﬁed products from 23 clinical samples and an EV-A71 iso-
late were sequenced in one batch. The run resulted in an output of
4.9 Gb, of which 60% could be successfully assembled. Over 92% of
the assembled bases had Phred quality scores of ≥30 (i.e. a probabil-
ity of ≥99.9% that the single bases were correctly sequenced). The
remaining bases had Phred quality scores of between >10 and 29
(i.e. >90% of accuracy). Twenty-three complete genome sequencesFig. 1. Agarose gel electrophoresis analysis of ampliﬁed products from 11 throat
swabs from HFMD patients; (A) PCR 1; (B) PCR 2; (C) PCR 3; lanes 1-11: clinical
samples, PC: positive control; NC: negative control; ampliﬁed products of expected
sizes are indicated by arrows.
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Table  2
Virus isolates and results of overlapping RT-PCRs.
EV-A71 strain Subgeno-group Accession number Location Year of isolation Overlapping RT-PCRs Subjected to Miseq sequencing
9522 C1 AY258300 Malaysia 2003 Positive No
8M/6/99 C2 AY126012 Australia 1999 Positive No
001-KOR-00 C3 AY125966 Korea 2000 Positive No
VN152  C4 Not available Vietnam 2011 Positive Yes
VN5559 C4 AM490152 Vietnam 2005 Positive No
VN5784 C5 AM490158 Vietnam 2005 Positive No
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213903  B3 AY207648 Malaysia 
A10/4  B4 AF376067 Malaysia 
18431  B5 Not available Malaysia 
80-fold in one other. Details of sequencing output per sample are
resented in Supplementary Appendix Table 2.
Phylogenetic analysis suggested that all viruses derived from
hroat swabs collected in 2013 belonged to EV-A71 subgenogroup
5 (Fig. 3), while the virus from culture material belonged to
ubgenogroup C4. This is in agreement with our initial typing result
ased on sequencing of VP1 region (data not shown).
.3. Minor variant detection
Using the criteria described in the Methods section, we  identi-
ed a total of 107 positions in the EV-A71 genome carrying minor
ariants (ranging from 0 to 15 variants per sample), of which 15
14%) were nonsynonymous. Interestingly, 73% (11/15) of the non-
ynonymous variants were present in the nonstructural protein
oding region, which also contained 65% of the total 107 vari-
nts observed, with mutations in the 2 C protein being the next
ost frequent (38/107, 35.5%). Most variants (101) represented
inor variants. However six variants were found to be either minor
r dominant (i.e. >50%) variants in different samples, suggesting
hat they may  impact viral ﬁtness in some way, and hence merit
dditional investigation. More details on the minor variants are pre-
ented Supplementary Appendix Table 3, including the frequency
ig. 2. Boxplots showing Cp values generated by an EV-A71 real time RT-PCR of RT-PCR p
9.2–35.5; P < 0.001.97 Positive No
00 Positive No
06 Positive No
of the six variants shared between viruses found in the data set of
279 genome sequences used in the present study.
4. Discussion
We have successfully developed a high-throughput Illumina
Miseq-based generic assay for direct whole-genome sequencing
of EV-A71 from clinical samples. Although primers for whole-
genome ampliﬁcation of EV-A71 have been proposed previously
(Shih et al., 2000; Cordey et al., 2012; Huang et al., 2009; Yoke-
Fun and AbuBakar, 2006; Chang et al., 2012; Zhang et al., 2013),
these primer sets were either large (i.e. at least eight combinations
were used) and/or not tested on diverse EV-A71 subgenogroups.
The procedure described here only requires three overlapping
PCRs to amplify the entire virus genome directly from clinical
specimens. In addition, the entire procedure from nucleic acid
extraction and PCR ampliﬁcation to obtaining a total of between
24 and 96 virus genomes takes approximately 5 days (Flowchart
1). The total reagent-associated cost is $120 USD per sample if
24 samples are multiplexed in one run (date of cost assessment:
July 2014). This can be reduced to $70 USD if 96 samples are
combined. In addition, with the great sequencing depth (i.e. a
single nucleotide is sequenced at least 500 times), the extent
ositive and negative groups, Cp value median; range: 28.2; 23.9–32.4 versus 31.2;
34 L.V. Tan et al. / Journal of Virological Methods 215–216 (2015) 30–36
Fig. 3. ML  phylogeny based on complete genomes (in bold) obtained in this study and t
was  obtained when VP1 sequences were analyzed separately (data not shown). The tree i
lengths are drawn to a scale of nucleotide substitutions per site. Bootstraps >70% are also
F
o
a
i
n
t
a
r
g
d
A
the next-generation sequencing error rate of 0.1% (Archer et al.,lowchart 1. Chart showing analysis procedure for obtaining the complete genome
f  EV-A71 from clinical samples.
nd pattern of intra-host genetic diversity data can be explored
n addition to the consensus sequence. It should however be
oted that although the current cost per genome is affordable,
he total cost per run (∼$3000 USD) together with hardware-
ssociated cost combined with bioinformatics challenges may
emain the major obstacles preventing Illumina based whole-
enome sequencing assay from being widely used, in particular in
eveloping countries including parts of Southeast Asia where EV-
71 and HFMD are endemic. Alternatively, generating full-lengthhose of representatives of EV-A71 downloaded from the GenBank. A similar result
s rooted on a single genogroup A sequence (USA/A/1970) and all horizontal branch
 shown. My: Malaysia, TW:  Taiwan, NL: the Netherlands, KOR: Korea, CHN: China.
virus sequence can be achieved using Sanger-sequencing-based
strategies (e.g. DNA walking of the obtained PCR amplicons
described in the present study and/or multiple small overlapping
PCRs spanning the whole virus genome). While the associated
cost per genome of such strategies might be comparable with
that of Illumina Miseq one, generating full-length virus genome
using Sanger sequencing technology is a laborious procedure as
it not possible to multiplex between 24 and 96 samples per run.
Likewise, with Sanger-sequencing data, exploring the pattern of
intra-host diversity of the pathogen at a level of frequency of 5% is
unachievable.
Using our procedure we were able to sequence viruses of
subgenogroup C4 and B5. Likewise, RNA from culture materials of
diverse EV-A71 subgenogroups belonging to both genogroup B and
C (Table 2) that have been associated with outbreaks of HFMD in
the Asia-Paciﬁc region since the 1990s was successfully ampliﬁed.
Assuming that a Cp value of ∼30 is the threshold of assay limit
of detection (Fig. 2), our observational data on Cp values obtained
from 824 throat swabs from HFMD patients in Vietnam (data not
shown) show that 75% of viruses in RT-PCR positive throat swabs
can be sequenced by our assay. Of note, among 65 tested swabs,
in the majority of cases the procedure failure was  attributed to
the RT-PCRs that generated the largest amplicon (RT-PCR 1) and/or
targeted at the genetically variable regions of the virus genome (RT-
PCR 2) (Supplementary Appendix Table 1), which may  suggest that
fragment size and/or sequence variations play a part in addition to
the viral-load factor.
We  conservatively chose cut-off values of 500-fold coverage and
a frequency of 5% for detection of minor variants. This is well above2012), while a previous study suggested that a coverage of >400-
fold is required for reliable detection of minor variants present at
1% in next generation sequencing data (Wang et al., 2007).
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Although an association between EV-A71 subgenogroups and
isease severity has not been identiﬁed, previous studies have
hown potential associations between single nucleotide variants
nd clinical severity (Cordey et al., 2012; Zhang et al., 2014). In
ddition, a recent study of C4, B1, B2 and B5 sequences found that
onsynonymous and synonymous substitutions occurred more fre-
uently in the nonstructural than the structural protein-coding
egion, suggesting that the former was a major ﬁtness determinant
Huang et al., 2014). We  similarly observed a majority of minor
ariants (including nonsynonymous ones) in the nonstructural
rotein-coding region, although the function of these mutations
s uncertain. As a consequence, these data further emphasize the
eed to study viral diversity and evolution at the whole-genome
evel, rather than in the VP1 protein alone which has been the main
ocus to date. Likewise, exploring the association between speciﬁc
iral genotypes/single nucleotide polymorphisms and clinical phe-
otype is clearly an area of importance, although beyond the scope
f the present study.
Our analysis of EV-A71 strains sampled in 2013 showed that
hey all belonged to subgenogroup B5, representing the ﬁrst report
f this subgenogroup in Vietnam, while subgenogroup C4 caused
he large outbreak of HFMD that occurred in Vietnam in 2011–12
Khanh et al., 2012). Subgenogroup switches commonly occur in
ther countries of Asia-Paciﬁc region where EV-A71 and HFMD
re endemic (Solomon et al., 2010), although the evolutionary
nd epidemiological processes responsible for these switches are
till unclear. Taken together, these data highlight the impor-
ance of studying spatial and temporal dynamics of EV-A71 across
ndemic countries, which may  in turn inform the development of
ntervention strategies, including vaccine development and imple-
entation, and can now be facilitated by the availability of a high
hroughput/cost-effective whole-genome sequencing procedure.
In conclusion, we  have successfully developed a high-
hroughput next-generation sequencing-based generic assay for
irect whole-genome sequencing of EV-A71 from clinical samples
hat provides important insights into viral diversity and evolution.
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